An updated meta-analysis of 23 case-control studies on the association between miR-34b/c polymorphism and cancer risk
Metrics: PDF 1096 views | HTML 1604 views | ?
Hua Li1,*, Shuling Diao2,*, Jingsen Li2, Baoxin Ma2, Shuanghu Yuan3
1Department of Oncology, The Affiliated Hospital of Binzhou Medical University, Binzhou, Shandong 256603, China
2Department of Cardiology, The Affiliated Hospital of Binzhou Medical University, Binzhou, Shandong 256603, China
3Department of Radiotherapy, Shandong Cancer Hospital and Institute, Jinan, Shandong 250117, China
*These authors have contributed equally to this work
Baoxin Ma, email: email@example.com
Keywords: rs4938723, polymorphism, cancer risk, systematic review, meta-analysis
Received: October 15, 2016 Accepted: February 27, 2017 Published: March 17, 2017
The association between in microRNA-34b/c gene rs4938723 polymorphisms and cancer risk remains inconclusive. This meta-analysis was performed to analyze the association between microRNA-34b/c rs4938723 polymorphism and risk for cancer development. In total, 304 studies from PubMed, Embase, Web of Science, Wanfang, and Chinese National Knowledge Infrastructure databases were examined, and 23 studies were included in this meta-analysis. The 23 selected studies involved 10,812 cancer cases and 11,719 controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to measure the strength of the association. Our results indicate a significant association between the rs4938723 polymorphism and cancer risk in the overdominant model (P heterogeneity = 0.018, OR = 1.093, and 95% CI = 1.015–1.177 for CT vs. CC/TT). Using a stratified subgroup analysis, rs4938723 polymorphisms were associated with an increased risk for hepatocellular carcinoma, but decreased risk for colorectal, gastric, and esophageal squamous cell cancer. These findings indicate that the rs4938723 gene is a susceptible locus for cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.